[{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"},{"id":"0db68b48-63b4-415c-9bee-7380074c53b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396859","created_at":"2022-05-31T12:54:45.824Z","updated_at":"2024-07-02T16:35:14.538Z","phase":"Phase 1","brief_title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT05396859","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • RUNX1 • MAPK1 • NTRK • MAPK3","pipe":" | ","alterations":" TP53 mutation • NTRK expression","tags":["TP53 • RUNX1 • MAPK1 • NTRK • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-15"},{"id":"976662e5-c9f9-45e1-a8a7-ec85c4257402","acronym":"","url":"https://clinicaltrials.gov/study/NCT01387724","created_at":"2021-01-18T05:41:39.859Z","updated_at":"2024-07-02T16:37:31.996Z","phase":"","brief_title":"Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma","source_id_and_acronym":"NCT01387724","lead_sponsor":"Children's Oncology Group","biomarkers":" NTRK2 • MYCN • BDNF","pipe":" | ","alterations":" MYCN amplification • MYCN expression • NTRK expression","tags":["NTRK2 • MYCN • BDNF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCN expression • NTRK expression"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-18"}]